Current Status of Clinical Development for Gene Therapy with Sendai Virus Vector Expressing the Human Fgf-2 Gene (Dvc1-0101) to Treat Peripheral Arterial Disease

被引：0
|
作者：
Tanaka, Michiko [1 ]
Harada, Yui [1 ]
Yonemitsu, Yoshikazu [1 ]
机构：
[1] Kyushu Univ, Fukuoka, Japan
来源：
MOLECULAR THERAPY | 2018年 / 26卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
765
引用
收藏
页码：350 / 350
页数：1
相关论文
共 9 条
  • [1] Current status of clinical development for gene therapy with Sendai virus vector expressing the human FGF-2 gene (DVC1-0101) to treat peripheral arterial disease
    Tanaka, M.
    Yonemitsu, Y.
    HUMAN GENE THERAPY, 2018, 29 (12) : A137 - A137
  • [2] An Update Progress Report of Clinical Safety and Efficacy for Gene Therapy with Sendai Virus Vector Expressing the Human FGF-2 Gene (DVC1-0101) to Treat Peripheral Arterial Disease
    Tanaka, Michiko
    Harada, Yui
    Yonemitsu, Yoshikazu
    MOLECULAR THERAPY, 2019, 27 (04) : 249 - 250
  • [3] R&D of DVC1-0101 as a new class of RNA gene medicine to treat peripheral arterial disease
    Yonemitsu, Yoshikazu
    Matsumoto, Takuya
    Maehara, Yoshihiko
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2015, 128 (03) : S55 - S55
  • [4] DVC1-0101 to Treat Peripheral Arterial Disease: A Phase I/IIa Open-label Dose-escalation Clinical Trial
    Yonemitsu, Yoshikazu
    Matsumoto, Takuya
    Itoh, Hiroyuki
    Okazaki, Jin
    Uchiyama, Makiko
    Yoshida, Kumi
    Onimaru, Mitsuho
    Onohara, Toshihiro
    Inoguchi, Hiroyuki
    Kyuragi, Ryoichi
    Shimokawa, Mototsugu
    Ban, Hiroshi
    Tanaka, Michiko
    Inoue, Makoto
    Shu, Tsugumine
    Hasegawa, Mamoru
    Nakanishi, Yoichi
    Maehara, Yoshihiko
    MOLECULAR THERAPY, 2013, 21 (03) : 707 - 714
  • [5] Gene therapy with recombinant Sendai virus vector for peripheral arterial disease: 1-year follow-up of QOL scores
    Tanaka, M.
    Imamura, M.
    Yoshida, K.
    Yonemitsu, Y.
    HUMAN GENE THERAPY, 2016, 27 (11) : A98 - A98
  • [6] Phase I/IIa, Open-Labeled, Dose Escalation Clinical Study Using FGF-2 Gene Mounted Sendai Virus Vector for Critically Ischemic Limbs
    Matsumoto, Takuya
    Yonemitsu, Yoshikazu
    Itoh, Hiroyuki
    Okazaki, Jin
    Uchiyama, Makiko
    Yoshida, Kumi
    Onohara, Toshihiro
    Hiroyuki, Inoguchi
    Kyuragi, Ryoichi
    Guntani, Atsushi
    Shimokawa, Mototsugu
    Onimaru, Mitsuho
    Ban, Hiroshi
    Makoto, Inoue
    Zhu, Tsugumine
    Hasegawa, Mamoru
    Nakanishi, Yoichi
    Maehara, Yoshihiko
    JOURNAL OF GENE MEDICINE, 2014, 16 (7-8): : 211 - 212
  • [7] Gene Transfer Therapy by Either Type 1 or Type 2 Adeno-Associated Virus Expressing Human Prostaglandin I2 Synthase Gene is Effective for Treatment of Pulmonary Arterial Hypertension
    Kataoka, Masaharu
    Kawakami, Takashi
    Tamura, Yuichi
    Yoshino, Hideaki
    Satoh, Toru
    Tanabe, Tadashi
    Fukuda, Keiichi
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2013, 18 (01) : 54 - 59
  • [8] The GuardOne clinical trial: A first-in-human, open-label, multinational phase 1/2 study of AVR-RD-02 ex vivo lentiviral vector, autologous gene therapy for Gaucher disease
    Jacobsen, Leslie
    Kerner, Julie A.
    Ciotti, Rachel
    Golipour, Azadeh
    Yang, Josie
    Pfeifer, Richard
    Khan, Aneal
    Mason, Chris
    MOLECULAR GENETICS AND METABOLISM, 2021, 132 (02) : S51 - S52
  • [9] The GuardOne clinical trial: a first in-human, open-label, multinational phase 1/2 study of AVR-RD-02 ex vivo lentiviral vector, autologous gene therapy for Gaucher disease
    Ridha, E.
    Jones, J. J.
    Abrahamsen, I.
    Golipour, A.
    Pfeifer, R.
    Khan, A.
    Mason, C.
    Escolar, D.
    HUMAN GENE THERAPY, 2021, 32 (19-20) : A80 - A80
1